Cargando…

Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment

BACKGROUND: Hemolysis, a rare but potentially serious complication of intravenous immunoglobulin (IVIG) therapy, is associated with the presence of antibodies to blood groups A and B (isoagglutinins) in the IVIG product. An immunoaffinity chromatography (IAC) step in the production process could dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerber, Simon, Gaida, Annette, Spiegl, Nicole, Wymann, Sandra, Antunes, Adriano Marques, Menyawi, Ibrahim El, Zurbriggen, Brigitte, Hubsch, Alphonse, Imboden, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054059/
https://www.ncbi.nlm.nih.gov/pubmed/27646589
http://dx.doi.org/10.1007/s40259-016-0192-3
_version_ 1782458516803420160
author Gerber, Simon
Gaida, Annette
Spiegl, Nicole
Wymann, Sandra
Antunes, Adriano Marques
Menyawi, Ibrahim El
Zurbriggen, Brigitte
Hubsch, Alphonse
Imboden, Martin
author_facet Gerber, Simon
Gaida, Annette
Spiegl, Nicole
Wymann, Sandra
Antunes, Adriano Marques
Menyawi, Ibrahim El
Zurbriggen, Brigitte
Hubsch, Alphonse
Imboden, Martin
author_sort Gerber, Simon
collection PubMed
description BACKGROUND: Hemolysis, a rare but potentially serious complication of intravenous immunoglobulin (IVIG) therapy, is associated with the presence of antibodies to blood groups A and B (isoagglutinins) in the IVIG product. An immunoaffinity chromatography (IAC) step in the production process could decrease isoagglutinin levels in IVIG. OBJECTIVES: Our objectives were to compare isoagglutinin levels in a large number of IVIG (Privigen(®)) batches produced with or without IAC and to assess the feasibility of the production process with an IAC step on an industrial scale. METHODS: The IAC column comprised a blend of anti-A and anti-B resins formed by coupling synthetic blood group antigens (A/B-trisaccharides) to a base bead matrix, and was introduced towards the end of the industrial-scale IVIG manufacturing process. Isoagglutinin levels in IVIG were determined by anti-A and anti-B hemagglutinin direct and indirect methods according to the European Pharmacopoeia (Ph. Eur.) and an isoagglutinin flow cytometry assay. IVIG product quality was assessed with respect to the retention of immunoglobulin G (IgG) subclasses, specific antibodies, and removal of IgM using standardized procedures. RESULTS: The IAC step reduced isoagglutinins in IVIG by two to three titer steps compared with lots produced without IAC. The median anti-A and anti-B titers with IAC were 1:8 and 1:4, respectively, when measured by the Ph. Eur. direct method, and 1:2 and <1, respectively, when measured by the Ph. Eur. indirect method. The isoagglutinin flow cytometry assay showed an 87–90 % reduction in isoagglutinins in post-IAC versus pre-IAC fractions. IAC alone reduced anti-A and anti-B of the IgMs isotype by 92.5–97.8 % and 95.4–99.2 %, respectively. Other product quality characteristics were similar with and without IAC. CONCLUSIONS: IAC is an effective method for reducing isoagglutinin levels in IVIG, and it is feasible on an industrial scale.
format Online
Article
Text
id pubmed-5054059
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-50540592016-10-24 Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment Gerber, Simon Gaida, Annette Spiegl, Nicole Wymann, Sandra Antunes, Adriano Marques Menyawi, Ibrahim El Zurbriggen, Brigitte Hubsch, Alphonse Imboden, Martin BioDrugs Original Research Article BACKGROUND: Hemolysis, a rare but potentially serious complication of intravenous immunoglobulin (IVIG) therapy, is associated with the presence of antibodies to blood groups A and B (isoagglutinins) in the IVIG product. An immunoaffinity chromatography (IAC) step in the production process could decrease isoagglutinin levels in IVIG. OBJECTIVES: Our objectives were to compare isoagglutinin levels in a large number of IVIG (Privigen(®)) batches produced with or without IAC and to assess the feasibility of the production process with an IAC step on an industrial scale. METHODS: The IAC column comprised a blend of anti-A and anti-B resins formed by coupling synthetic blood group antigens (A/B-trisaccharides) to a base bead matrix, and was introduced towards the end of the industrial-scale IVIG manufacturing process. Isoagglutinin levels in IVIG were determined by anti-A and anti-B hemagglutinin direct and indirect methods according to the European Pharmacopoeia (Ph. Eur.) and an isoagglutinin flow cytometry assay. IVIG product quality was assessed with respect to the retention of immunoglobulin G (IgG) subclasses, specific antibodies, and removal of IgM using standardized procedures. RESULTS: The IAC step reduced isoagglutinins in IVIG by two to three titer steps compared with lots produced without IAC. The median anti-A and anti-B titers with IAC were 1:8 and 1:4, respectively, when measured by the Ph. Eur. direct method, and 1:2 and <1, respectively, when measured by the Ph. Eur. indirect method. The isoagglutinin flow cytometry assay showed an 87–90 % reduction in isoagglutinins in post-IAC versus pre-IAC fractions. IAC alone reduced anti-A and anti-B of the IgMs isotype by 92.5–97.8 % and 95.4–99.2 %, respectively. Other product quality characteristics were similar with and without IAC. CONCLUSIONS: IAC is an effective method for reducing isoagglutinin levels in IVIG, and it is feasible on an industrial scale. Springer International Publishing 2016-09-19 2016 /pmc/articles/PMC5054059/ /pubmed/27646589 http://dx.doi.org/10.1007/s40259-016-0192-3 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Gerber, Simon
Gaida, Annette
Spiegl, Nicole
Wymann, Sandra
Antunes, Adriano Marques
Menyawi, Ibrahim El
Zurbriggen, Brigitte
Hubsch, Alphonse
Imboden, Martin
Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment
title Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment
title_full Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment
title_fullStr Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment
title_full_unstemmed Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment
title_short Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment
title_sort reduction of isoagglutinin in intravenous immunoglobulin (ivig) using blood group a- and b-specific immunoaffinity chromatography: industry-scale assessment
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054059/
https://www.ncbi.nlm.nih.gov/pubmed/27646589
http://dx.doi.org/10.1007/s40259-016-0192-3
work_keys_str_mv AT gerbersimon reductionofisoagglutinininintravenousimmunoglobulinivigusingbloodgroupaandbspecificimmunoaffinitychromatographyindustryscaleassessment
AT gaidaannette reductionofisoagglutinininintravenousimmunoglobulinivigusingbloodgroupaandbspecificimmunoaffinitychromatographyindustryscaleassessment
AT spieglnicole reductionofisoagglutinininintravenousimmunoglobulinivigusingbloodgroupaandbspecificimmunoaffinitychromatographyindustryscaleassessment
AT wymannsandra reductionofisoagglutinininintravenousimmunoglobulinivigusingbloodgroupaandbspecificimmunoaffinitychromatographyindustryscaleassessment
AT antunesadrianomarques reductionofisoagglutinininintravenousimmunoglobulinivigusingbloodgroupaandbspecificimmunoaffinitychromatographyindustryscaleassessment
AT menyawiibrahimel reductionofisoagglutinininintravenousimmunoglobulinivigusingbloodgroupaandbspecificimmunoaffinitychromatographyindustryscaleassessment
AT zurbriggenbrigitte reductionofisoagglutinininintravenousimmunoglobulinivigusingbloodgroupaandbspecificimmunoaffinitychromatographyindustryscaleassessment
AT hubschalphonse reductionofisoagglutinininintravenousimmunoglobulinivigusingbloodgroupaandbspecificimmunoaffinitychromatographyindustryscaleassessment
AT imbodenmartin reductionofisoagglutinininintravenousimmunoglobulinivigusingbloodgroupaandbspecificimmunoaffinitychromatographyindustryscaleassessment